June 2026 in “DOAJ (DOAJ: Directory of Open Access Journals)” New therapies for alopecia areata show promise but need more research and collaboration.
Spironolactone may be a better acne treatment for adult women than antibiotics.
6 citations
,
January 2024 in “International Journal of Dermatology” Monoclonal antibodies are often linked to alopecia areata cases.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
1 citations
,
May 2024 in “Italian Journal of Dermatology and Venereology” Alopecia areata is hard to manage and affects quality of life.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
19 citations
,
June 2018 in “Breast Cancer Research and Treatment” Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
June 2026 in “DOAJ (DOAJ: Directory of Open Access Journals)” Upadacitinib effectively treated alopecia areata when other treatments failed.
555 citations
,
April 2002 in “The Lancet” Off-pump heart surgery reduces complications without affecting survival rates compared to on-pump surgery.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” Oral prednisolone helps hair regrowth in alopecia areata.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
June 2026 in “British Journal of Dermatology” Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
January 2026 in “The FASEB Journal” The trial aims to test a new treatment for hair loss in young men using stem cell-derived vesicles.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
STS01 1% effectively promotes hair regrowth with minimal side effects.
The treatment was not recommended due to limited effectiveness and significant side effects.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
88 citations
,
January 2001 in “Dermatology” EE/CMA is more effective than EE/LNG in reducing acne.
20 citations
,
February 2004 in “Clinical & Experimental Immunology” SADBE treatment led to complete hair regrowth in mice with alopecia areata by altering immune cell movement.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.